Directors Dealings / Market Share Purchases

RNS Number : 0372D

Oxford Biomedica PLC

24 June 2021

 

Directors Dealings / Market Share Purchases

Oxford, UK - 24 June 2021:   Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces   that two of the Company's Non-Executive Directors have purchased shares in the Company.  

As stated in the Oxford Biomedica 2021 Remuneration Policy which was approved at the 2021 Annual General Meeting, an additional fee of up to £50,000 per annum may be paid to any Non-Executive Director recruited from or based in the United States to reflect market levels of remuneration in the United States for Non-Executive Directors, subject to their agreement that the after tax amount of this additional fee will be applied in the acquisition of Oxford Biomedica shares at market value, which must be retained for at least 12 months from acquisition.

Dr. Heather Preston, Non-Executive Director of the Group, has purchased 2,235 ordinary shares of 50p each ("Ordinary Shares") in the Company on 23 June 2021 on the London Stock Exchange at a price of 1288p under the terms of a market purchase agreement. Following this purchase Dr. Heather Preston holds 2,235 Ordinary Shares representing 0.003% of the Company.

Dr. Siyamak Rasty, Non-Executive Director of the Group, has purchased 2,235 Ordinary Shares in the Company on 23 June 2021 on the London Stock Exchange at a price of 1288p under the terms of a market purchase agreement. Following this purchase Dr. Siyamak Rasty holds 2,235 Ordinary Shares representing 0.003% of the Company.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of ordinary shares purchased.

1.	Details of the person discharging material responsibilities/person closely   associated
a.	Name	Heather Preston
2.	Reason for the notification
a.	Position/status	Non-Executive Director
b.	Initial notification /amendment	Initial notification
3.	Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford Biomedica plc
b.	Legal Entity Identifier	213800S1GVQNXQ15K851
4.	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument identification code	Oxford Biomedica plc Ordinary Shares of 50p each  GB00BDFBVT43
b.	Nature of the transaction	Purchase of ordinary shares
c.	Currency	GBP - British Pound
d.	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.88	2,235
e.	Aggregated information · Aggregated volume · Price · Aggregated total	2,235  12.88  28,786.80
f.	Date of the transaction	2021-06-23
g.	Place of the transaction	London Stock Exchange, Main Market (XLON)

1.	Details of the person discharging material responsibilities/person closely   associated
a.	Name	Siyamak Rasty
2.	Reason for the notification
a.	Position/status	Non-Executive Director
b.	Initial notification /amendment	Initial notification
3.	Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford Biomedica plc
b.	Legal Entity Identifier	213800S1GVQNXQ15K851
4.	Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument identification code	Oxford Biomedica plc Ordinary Shares of 50p each  GB00BDFBVT43
b.	Nature of the transaction	Purchase of ordinary shares
c.	Currency	GBP - British Pound
d.	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.88	2,235
e.	Aggregated information · Aggregated volume · Price · Aggregated total	2,235  12.88  28,786.80
f.	Date of the transaction	2021-06-23
g.	Place of the transaction	London Stock Exchange, Main Market (XLON)

The issued share capital of the Group is 82,591,804 Ordinary Shares.

-Ends-

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: [phone]

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a three year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 670 people. Further information is available at www.oxb.com

 

END

 

 

DSHSEAFFLEFSEDM